Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.86 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14775025 | 0.92 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3TP53MAPT | |
| SCHEMBL14775565 | 0.85 | SLC6A4 (0.86) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14775283 | 0.80 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3HRH3SIGMAR1 | |
| SCHEMBL14775381 | 0.79 | SLC6A2 (0.71) | SLC6A4SLC6A2SLC6A3DPP4TACR2 | |
| SCHEMBL14775500 | 0.79 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3TP53TACR2 | |
| SCHEMBL14775389 | 0.78 | SLC6A2 (0.74) | SLC6A4SLC6A2SLC6A3TP53MAPT | |
| SCHEMBL14775083 | 0.77 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14775196 | 0.74 | SLC6A2 (1.00) | SLC6A4SLC6A2SLC6A3SIGMAR1 | |
| SCHEMBL14775366 | 0.73 | SLC6A2 (0.67) | SLC6A4SLC6A2SLC6A3TP53MAPT | |
| SCHEMBL14775127 | 0.72 | SLC6A2 (0.66) | SLC6A4SLC6A2SLC6A3TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570409-B1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | SHANGHAI INST PHARM INDUSTRY (CN) | 2015-07-08 | — | — | EP | claimed |
| US-8962621-B2 | Aralkyl diamine derivatives and uses thereof as antidepressants | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-02-24 | — | — | US | claimed |
| US-20130072488-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-03-21 | — | — | US | claimed |
| EP-2570409-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-03-20 | — | — | EP | claimed |
| EP-2570409-B1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | SHANGHAI INST PHARM INDUSTRY (CN) | 2015-07-08 | — | — | EP | disclosed |
| US-8962621-B2 | Aralkyl diamine derivatives and uses thereof as antidepressants | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-20130072488-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-03-21 | — | — | US | disclosed |
| EP-2570409-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072488-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS | MAOA, SLC6A2, MAOB | SLC6A4 5/4885SLC6A2 2/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.